Multivalent heteromultimer scaffold design and constructs
US-9499605-B2 · Nov 22, 2016 · US
Fusion protein having factor IX activity
US9617328B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9617328-B2 |
| Application number | US-201113880239-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 19, 2011 |
| Priority date | Oct 20, 2010 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A fusion protein comprising human-derived factor IX (FIX) and human-derived transferrin, wherein the fusion protein comprises a linker between the FIX and the transferrin, said linker being the amino acid sequence of SEQ ID NO: 9 or 11; wherein the FIX amino acid sequence has 95% or higher identity to the amino acid sequence of SEQ ID NO: 1; and wherein the transferrin amino acid sequence has 95% or higher identity to the amino acid sequence of SEQ ID NO: 2. 2. A gene encoding the fusion protein of claim 1 . 3. The gene of claim 2 , wherein the gene has the nucleotide sequence of SEQ NO: 20 or 21. 4. A recombinant vector comprising the gene of claim 3 . 5. An isolated host cell comprising the recombinant vector of claim 4 therein. 6. The host cell of claim 5 , wherein the host cell is selected from the group consisting of a CHO cell, a BHK-21 cell, an HEK293 cell, and a HepG2 cell.
Assignees
Inventors
Classifications
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
- C07K14/79Primary
Transferrins, e.g. lactoferrins, ovotransferrins · CPC title
Coagulation factor IXa (3.4.21.22) · CPC title
- C07K19/00Primary
Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title
Blood coagulation or fibrinolysis factors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9617328B2 cover?
- Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
- Who is the assignee on this patent?
- Lee Min Sun, Kim Hun-Taek, Lee Bong-Yong, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/79. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).